Compare · CBLL vs ZYXI
CBLL vs ZYXI
Side-by-side comparison of CeriBell Inc. (CBLL) and Zynex Inc. (ZYXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and ZYXI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CBLL carries a market cap of $1.00B.
- CBLL has hit the wire 11 times in the past 4 weeks while ZYXI has been quiet.
- ZYXI has more recent analyst coverage (10 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- Zynex Inc.
- Price
- -
- -
- Market cap
- $1.00B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- News (4w)
- 11
- 0
- Recent ratings
- 8
- 10
Zynex Inc.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Latest CBLL
- Director Josef Parvizi sold $650,500 worth of shares (25,000 units at $26.02) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by CeriBell Inc.
- Director Burke William W exercised 18,000 shares at a strike of $4.70 and sold $479,480 worth of shares (18,000 units at $26.64) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by CeriBell Inc.
- Director Taylor Joseph Michael sold $277,644 worth of shares (10,200 units at $27.22), decreasing direct ownership by 21% to 38,278 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $131,754 worth of shares (4,887 units at $26.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by CeriBell Inc.
- CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ceribell Reports Third Quarter 2026 Financial Results
- Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Latest ZYXI
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Zynex Financial Restructuring Puts Company on Path to Long-Term Success
- SEC Form 3 filed by new insider Aronzon Paul
- SEC Form 10-Q filed by Zynex Inc.
- Zynex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zynex Reports Third Quarter 2025 Financial Results
- Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee
- Zynex Sets Third Quarter 2025 Earnings Call
- SEC Form NT 10-Q filed by Zynex Inc.